may be protected by formulation with phospholipids (Fricker et al.,
2010). The lack of sufficient attention to lipid-based formulations
prior to clinical testing on insoluble molecules, especially those
with low or variable oral bioavailability in conventional formulations,
has led to a dearth of applications for this technology and
only 2–4% of the commercially available drug products formulated
relies on such technology (Hauss, 2007; Khani and Keyhanfar,
2014).
developing stable and safe drug dispersions since their acceptance
by regulatory agencies and extensive history of use make them
useful excipients in formulations intended for oral, topical, and
intravenous delivery (Khani and Keyhanfar, 2014). A further
advantage of phospholipids formulations in oral drug delivery is
that drugs susceptible to decomposition by enzymes in the GI tract